SIOPEN

  • International Society of Paediatric Oncology Europe Neuroblastoma

Myeloablative chemotherapy: BuMel versus CEM

Busulfan.jpg

In the most recent SIOPEN High-Risk neuroblastoma study, two different combinations of myeloablative (high-dose) chemotherapy were compared.

A total of 1577 patients were randomised to receive either BuMel (busulfan and melphalan) or CEM (carboplatin, etoposide and melphalan). The results showed a significantly better outcome for patients treated with BuMel compared to CEM (event free survival at 3 years of 49% vs 33%; overall survival at 3 years 60% vs 48%). In addition, the study showed that overall BuMel was less toxic than CEM.

In the light of these results, BuMel has now been adopted as the standard myeloablative (high-dose) chemotherapy for neuroblastoma patients treated by SIOPEN.

Link to abstract presented at ASCO Annual Meeting 2011

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information

SIOPEN

SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.